Similarly, the administration of siRNA PMP22 conjugated to squalene nanoparticles caused normalization of PMP22 protein levels, regeneration of myelinated axons and myelin compaction, and restored locomotor activity in two transgenic CMT1A mouse models [517]. Here, PMP22 is linked to Charcot-Marie-Tooth disease type 1A.